Immune cell therapy company ViGenCell Inc. has kept the biopharma investment fervor going in South Korea, raising KRW99.4bn ($85m) from an initial public offering on the Kosdaq market.
The stock was priced at the top end of the KRW42,800-52,700 band and the offering was oversubscribed 886.2 times by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?